atorvastatin / Generic mfg. - LARVOL DELTA

Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Central South University | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Psychiatry • Schizophrenia

Diabetic Striatopathy Presenting With Hemiballism: An Unusual Neurologic Complication Of Uncontrolled Type 2 Diabetes Mellitus (ENDO 2025) - "She is on aspirin 81 mg daily, atorvastatin 40 mg daily, carvedilol 25mg twice daily, chlorthalidone 50 mg daily, spironolactone 100 mg daily, losartan 50 mg daily and the combination of elvitegravir- cobicistat- emtricitabine-tenofovir alafenamide as 1 tablet daily.Physical exam showed dry mucous membranes, tachycardia, intermittent left upper extremity abduction and adduction movements, with no other motor or sensory deficits. Diabetic striatopathy is a rare neurologic complication of uncontrolled hyperglycemia, characterized by abnormal movement (hemichorea/ hemiballism). The most common radiologic finding is hyperdensity in the contralateral putamen and/or caudate nucleus on CT scan. Management relies on the correction of hyperglycemia and the administration of antipsychotics (haloperidol, risperidone) or benzodiazepines(clonazepam)."

Late-breaking abstract • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Diabetes • Dyslipidemia • Hematological Disorders • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Metabolic Disorders • Movement Disorders • Pain • Type 2 Diabetes Mellitus

Amiodarone induced thyroiditis (ENDO 2025) - "He was initially diagnosed with suspected type 2 amiodarone induced thyroiditis and treated with a course of prednisone for 10 days...The rhabdomyolysis could be precipitated by the prolonged usage of amiodarone and atorvastatin which could have been worsened by prolonged amiodarone induced thyroiditis... Type 1 AIT is usually treated with thioamides, enhanced by potassium perchlorate to block iodine uptake, while type 2 AIT is best treated with oral glucocorticoids. Mixed forms may require a combination of these therapies. In refractory cases, thyroidectomy can be considered."

Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Endocrine Disorders • Fatigue • Hypertension • Musculoskeletal Pain • Myositis • Nephrology • Pain • Renal Disease

A Rare Sight: Isolated Third Nerve Palsy as the Sole Presentation of a Non-Functional Pituitary Adenoma (ENDO 2025) - "He was treated with hydrocortisone, levothyroxine, insulin and atorvastatin. Given the potential for diagnostic anchoring bias, clinicians should maintain a broad perspective when assessing neurological deficits. Prompt imaging and endocrine assessment are essential for timely diagnosis and management, ensuring appropriate intervention before significant complications arise."

Diabetes • Endocrine Cancer • Endocrine Disorders • Hematological Disorders • Metabolic Disorders • Oncology • Pain • Pituitary Gland Carcinoma • Type 2 Diabetes Mellitus • IGF1

When Metabolic Stress Meets Genetics: A Triad of DKA, Acute Pancreatitis, and Hypertriglyceridemia in a Patient with LMF1 Mutation (ENDO 2025) - "He had poor adherence to metformin, Jardiance, and pioglitazone, with an A1C of 10.7%...He was discharged on insulin, atorvastatin, and fenofibrate with a diabetes education referral...Data comparing insulin infusion and plasmapheresis for treating HTG in HTG-AP-DKA is limited. Plasmapheresis may be more effective in LPL deficiency cases, warranting further research in the future."

Clinical • Diabetes • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Pain • Pancreatitis • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus • LPL

Impact of GLP-1 Analogs vs. Lipid Lowering Agents on Risk for Acute Pancreatitis in Hypertriglyceridemia: A TriNetX Analysis (ENDO 2025) - "There were 21,106 patients receiving treatment with a GLP-1 analog (Cohort A) and 296,961 patients taking lipid lowering agents which we defined as atorvastatin, rosuvastatin, pravastatin, simvastatin, fenofibrate, ezetimibe, icosapent ethyl, evolocumab (Cohort B). Furthermore, it may reduce mortality for patients who have failed other modalities for weight loss, which is consistent with our findings. Ongoing research is essential to understand the long-term outcomes of GLP-1 analog therapy."

Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Obesity • Pancreatitis • Severe Hypertriglyceridemia

Giant Pancreatic Pseudocyst as a complication of Hypertriglyceridemia-Induced Pancreatitis (ENDO 2025) - "On day tenth, given clinical and biochemical improvement and a multidisciplinary team discussion, patient was discharged on metformin, fenofibrate, atorvastatin, pioglitazone, and vascepa, with plan for GI follow-up for possible necrosectomy. This case reports rare occurrence of HTG-induced necrotizing pancreatitis with the formation of giant pancreatic pseudocyst. It also illustrates the importance of timely intervention and proper management of severe hypertriglyceridemia, to reduce the risk of complications including necrotizing pancreatitis and pseudocyst. Long-term management should be focused on alleviating the effects of metabolic syndrome by addressing related factors like diabetes and obesity."

Diabetes • Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Metabolic Disorders • Obesity • Pain • Pancreatitis • Severe Hypertriglyceridemia

Pharmacological Approaches in Lipodystrophy: Concomitant Medication and Metreleptin Therapy Use in the Participants of LD-Lync Study (ENDO 2025) - P | "Metformin was the most commonly used antidiabetic agent, particularly in FPLD (n=101), followed by CGL (n=21), APL (n=10), and AGL (n=5)...Fenofibrate was used by 79 patients, with the highest prevalence observed in the CGL (48%) and FPLD (35%) subgroups. Statins, primarily atorvastatin (n=57) and rosuvastatin (n=25), were the most prescribed lipid-lowering agents, and were used by 100 patients overall, including 47.9% of those in the FPLD subgroup...Omega-3 derivatives were used by 53 patients (19%), while niacin and cholestyramine were used by only two patients... This study highlights the heterogeneity in pharmacological management across lipodystrophy subtypes, reflecting their diverse metabolic profiles and needs. While metreleptin remains the cornerstone therapy for generalized lipodystrophy, there is a need for novel therapeutic options to achieve improved metabolic control and optimize treatment outcomes in partial lipodystrophy."

Dyslipidemia • Lipodystrophy • Metabolic Disorders • Rare Diseases

Dancing with Diabetes: Unmasking Diabetic Striatopathy as a Rare Cause of Hemichorea (ENDO 2025) - "She was started on aspirin and atorvastatin and admitted to the stroke unit...Initial treatment for hemichorea with a GABA-receptor agonist was ineffective, and she declined haloperidol due to concerns about side effects. Clonazepam was subsequently initiated, resulting in an improvement of her choreiform movements alongside strict glucose control...The prognosis is excellent, with one case series reporting that 74% of patients achieved complete resolution of chorea within a period ranging from 1 hour to 10 months following appropriate glycemic management. This case report aims to raise awareness of a potential differential diagnosis for movement disorders, particularly in patients with poorly controlled diabetes."

Cardiovascular • Cerebral Hemorrhage • Diabetes • Dyslipidemia • Hematological Disorders • Hypertension • Metabolic Disorders • Movement Disorders • Type 2 Diabetes Mellitus

Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis (ENDO 2025) - "The FDA recently approved resmetirom, a liver-directed β-selective thyroid hormone receptor agonist, for MASH with significant fibrosis...Treating mice with antisense oligonucleotides (ASOs) against Coenzyme A synthase (Cosay), Cell Death-inducing DNA fragmentation factor-like effector B (CideB), hydroxysteroid 17-beta dehydrogenase 13 (Hsd17b13) or treatment with bempedoic acid or atorvastatin decreased liver lipid droplet cholesterol content and prevented CDAHFD-induced MASH and the fibrotic response...Conclusions Our findings identify cholesterol in liver lipid droplets as a critical mediator of MASH and demonstrate that COASY, CIDEB, HSD17B13 knockdown and bempedoic acid are novel therapeutic approaches to reduce liver lipid droplet cholesterol content and thereby prevent the development of MASH and liver fibrosis. In addition, this mechanism broadly links to human MASH pathogenesis and is associated with gene variants, including PNPLA3 and HSD17B13."

Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • COL1A1 • PNPLA3

Plasmapheresis as Salvage Therapy for Refractory Hypertriglyceridemia-Induced Pancreatitis Unresponsive to Insulin (ENDO 2025) - "Endocrinology recommended a long-term lipid management strategy, including fibrates, omega-3 fatty acids, and atorvastatin...Additionally, resource availability and expertise play a critical role in determining its application. Triglycerides (<150) and lipase (10-140)."

Addiction (Opioid and Alcohol) • Cardiovascular • Diabetes • Dyslipidemia • Endocrine Disorders • Hematological Disorders • Hypertension • Hypertriglyceridemia • Infectious Disease • Inflammation • Metabolic Disorders • Pain • Pancreatitis • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus

Evinacumab as an Effective Treatment Option for Refractory Hypertriglyceridemia (ENDO 2025) - "Despite using atorvastatin 80 mg daily, fenofibrate 162 mg daily, icosapent ethyl 2 g twice daily, and evolocumab 140 mg every 2 weeks, she continued to have hypertriglyceridemia. Evinacumab may be an effective alternative agent for the management of chronic hypertriglyceridemia based on the robust effects seen in our patient. Future research is needed to explore evinacumab's therapeutic targets beyond LDL-C to better modify risk factors for atherosclerosis, as well as CAV progression in heart transplant recipients."

Atherosclerosis • Cardiomyopathy • Cardiovascular • Diabetes • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus • ANGPTL3 • APOB

Beta-Shift Phenomenon Following Resolution of Diabetic Ketoacidosis: A Case Report (ENDO 2025) - "During prolonged fasting or states of diabetic ketoacidosis (DKA) where insulin levels fall, LPL activity decreases.Clinical Case: A 58-year-old female with hyperlipidemia and type 2 diabetes mellitus (non-adherence with metformin and basal-bolus insulin) is admitted to the medical intensive care unit for DKA...Upon review of her outside records, it appeared that her LDL had previously been as high as 175 mg/dL, however, after initiating Atorvastatin 80 mg, her last measured LDL was 100 mg/dL around two years prior...In our case, we did not have a triglyceride level before her DKA presentation, however, it was presumed to be significantly elevated in the setting of her severe insulin resistance and non-compliance. This phenomenon of temporary elevated LDL is known as the beta-shift and is diagnosed retrospectively once laboratory testing after discharge demonstrates resolution of the hypercholesterolemia; with persistence, the differential diagnosis of familial..."

Case report • Clinical • Diabetes • Dyslipidemia • Endocrine Disorders • Familial Hypercholesterolemia • Genetic Disorders • Metabolic Disorders • Type 2 Diabetes Mellitus • LPL

Suspected statin-related adverse drug reactions: analysis of spontaneous reports in Hubei Province, China (2014-2022). (PubMed, Expert Opin Drug Saf) - "ADR reports of atorvastatin and rosuvastatin were numerous and serious. Atorvastatin may cause off-label ADRs such as back pain, increased blood bilirubin, bone pain, hemorrhage, hepatic failure, and hepatocellular injury. Drug instructions should be enriched for better labeling of ADRs."

Adverse drug reaction • Journal • Back Pain • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Liver Failure • Musculoskeletal Pain • Pain

In vivo efficacy of atorvastatin in the treatment of Tinea pedis: stepping forward into drug repositioning. (PubMed, J Antibiot (Tokyo)) - "The results showed that the cutaneous delivery-atorvastatin showed total score reduction after seven days of treatment. We concluded that atorvastatin may be a promising drug for the treatment of superficial and cutaneous mycosis."

Journal • Preclinical • Dermatology

Atorvastatin unveiling primary biliary cholangitis and autoimmune hepatitis overlap syndrome in an older adult: A case report. (PubMed, Malays Fam Physician) - "We present the case of a 70-year-old woman who developed hepatocellular injury 4 months after switching from simvastatin to high-intensity atorvastatin. Treatment with prednisolone led to normalisation of liver function, and the patient remained stable on azathioprine and ursodeoxycholic acid. This case underscores the importance of vigilant liver function monitoring, caution when rechallenging statins and the potential for statin therapy to unmask underlying autoimmune liver disease."

Journal • Autoimmune Hepatitis • Dyslipidemia • Hepatology • Immunology • Inflammation • Primary Biliary Cholangitis

An Outpatient Pharmacist Strategy Improves Guideline Adherent Medication Prescribing in Patients with Vascular Disease. (PubMed, Eur J Vasc Endovasc Surg) - "Pharmacist review of patients in an outpatient vascular clinic is a likely effective strategy to improve prescribing rates of guideline adherent statin therapy and smoking cessation service provision."

Journal • Cardiovascular • Peripheral Arterial Disease • Tobacco Cessation

Fu-Fang-Qi-Di-Hua-Yu-Tang Improves Diabetic Macrovascular Disease via PI3K/AKT Pathway Regulation. (PubMed, Diabetes Metab Syndr Obes) - "Groups included control (C57BL/6), model (normal saline), low/medium/high-dose FFQD, and western medicine (atorvastatin + metformin)...FFQD may improve insulin resistance, regulate glucose and lipid metabolism, inhibit excessive autophagy, induce macrophage polarization, resist inflammation and oxidative stress, inhibit atherosclerosis, and ultimately improve DMD by activating the RAGE/PI3K/AKT/mTOR and RAP1/PI3K/AKT/FOX01 pathways. Therefore, FFQD may be a promising candidate for DMD treatment."

Journal • Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Metabolic Disorders • Oncology • APOE • CCL2 • CRP • IL1B • IL6 • MAP1A • NOS2 • RELA • SQSTM1 • TNFA

Efficacy of atorvastatin-based treatment in super-aged patients with chronic subdural hematoma: a case series and literature review. (PubMed, Front Neurol) - "This study evaluates the effects of atorvastatin, either as monotherapy or in combination with dexamethasone, in the conservative treatment of CSDH in patients over 90 years old, while also reviewing the current literature on the management of CSDH in this super-aged population. No mortality was recorded during the six-month follow-up. Our findings suggest that atorvastatin-based treatment may improve the prognosis of CSDH in super-aged patients and offer a viable therapeutic alternative for those ineligible for surgery."

Journal • CNS Disorders • Diabetes

When Being Overweight Masks the Diagnosis: Identifying Familial Hypercholesterolemia in Pediatric Patients. (PubMed, Cureus) - "Both siblings were started on atorvastatin 10 mg daily, resulting in significant LDL-C reduction without adverse effects...Obesity may mask FH, contributing to delays in recognition and management. Early clinical suspicion, comprehensive family screening, and timely initiation of statin therapy are essential for effective management of pediatric HeFH and the prevention of long-term cardiovascular complications."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Metabolic Disorders • Obesity • Pediatrics

Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification. (PubMed, J Hepatol) - "We unraveled the intriguing relationship between the mevalonate pathway, CoQ10 production, and selenoprotein translation. The anti-tumor roles of 6-FMEV and atorvastatin highlight the potential of targeting the pathway as a promising therapeutic strategy for HCC."

Journal • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • AIFM2 • GPX4 • MVD

Association of Medication Use and 8-Year Mortality Risk in Patients With Parkinson Disease: Drug-Wide Trial Emulation. (PubMed, Neurology) - "Our study identified several drugs with potential disease-modifying properties that could be candidates for future clinical trials. It highlights the potential of repurposing existing medications to advance drug development. While these findings are exploratory and, therefore, insufficient to justify immediate clinical application, they warrant further investigation and potential inclusion in clinical trials."

Journal • Observational data • CNS Disorders • Cough • Erectile Dysfunction • Infectious Disease • Movement Disorders • Ophthalmology • Pain • Parkinson's Disease • Respiratory Diseases

Impact of atorvastatin on serum oestradiol and estrone concentrations in postmenopausal women with chronic coronary artery disease: a randomized trial. (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular • Coronary Artery Disease

Atorvastatin and left ventricular global longitudinal strain during anthracycline-based chemotherapy (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular

Atorvastatin active metabolite inhibits oxidation of Lp(a), small dense LDL and triglyceride-rich lipoproteins compared to other statins through a free radical scavenging mechanism (ESC-WCC 2025) - No abstract available

Cardiovascular